189 related articles for article (PubMed ID: 17306255)
1. Leishmania major: in vitro and in vivo anti-leishmanial activity of paromomycin ointment (Leshcutan) combined with the immunomodulator Imiquimod.
El-On J; Bazarsky E; Sneir R
Exp Parasitol; 2007 Jun; 116(2):156-62. PubMed ID: 17306255
[TBL] [Abstract][Full Text] [Related]
2. Leishmania major: resistance of promastigotes to paromomycin, and susceptibility of amastigotes to paromomycin-methylbenzethonium chloride ointment.
el-On J; Sulitzeanu A; Schnur LF
Ann Trop Med Parasitol; 1991 Jun; 85(3):323-8. PubMed ID: 1746981
[TBL] [Abstract][Full Text] [Related]
3. Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin.
Grogl M; Schuster BG; Ellis WY; Berman JD
J Parasitol; 1999 Apr; 85(2):354-9. PubMed ID: 10219319
[TBL] [Abstract][Full Text] [Related]
4. Combination of paromomycin plus human anti-TNF-α antibodies to control the local inflammatory response in BALB/ mice with cutaneous leishmaniasis lesions.
Schwartz J; Moreno E; Calvo A; Blanco L; Fernández-Rubio C; Sanmartín C; Nguewa P; Irache JM; Larrea E; Espuelas S
J Dermatol Sci; 2018 Oct; 92(1):78-88. PubMed ID: 30037731
[TBL] [Abstract][Full Text] [Related]
5. The lack of effectiveness of hyperbaric oxygenation as a treatment for Leishmania major in a mouse model.
Livneh A; Youngster I; El-On Y; Berkovitch M; Abu-Kishk I
Acta Parasitol; 2015 Jun; 60(2):345-9. PubMed ID: 26204005
[TBL] [Abstract][Full Text] [Related]
6. Colloidal, in vitro and in vivo anti-leishmanial properties of transfersomes containing paromomycin sulfate in susceptible BALB/c mice.
Bavarsad N; Fazly Bazzaz BS; Khamesipour A; Jaafari MR
Acta Trop; 2012 Oct; 124(1):33-41. PubMed ID: 22750480
[TBL] [Abstract][Full Text] [Related]
7. Studies on the topical treatment of experimental cutaneous leishmaniasis: the therapeutic effect of methyl benzethonium chloride and the aminoglycosides, gentamicin and paromomycin.
Carter KC; Alexander J; Baillie AJ
Ann Trop Med Parasitol; 1989 Jun; 83(3):233-9. PubMed ID: 2604461
[TBL] [Abstract][Full Text] [Related]
8. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment of American cutaneous leishmaniasis: controlled study.
Krause G; Kroeger A
Clin Infect Dis; 1999 Aug; 29(2):466-7. PubMed ID: 10476776
[No Abstract] [Full Text] [Related]
9. Leishmania major: bacterial contamination of cutaneous lesions in experimental animals.
el-On J; Sneier R; Elias E
Isr J Med Sci; 1992 Dec; 28(12):847-51. PubMed ID: 1286954
[TBL] [Abstract][Full Text] [Related]
10. Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens.
Aguiar MG; Silva DL; Nunan FA; Nunan EA; Fernandes AP; Ferreira LA
J Antimicrob Chemother; 2009 Dec; 64(6):1234-40. PubMed ID: 19825819
[TBL] [Abstract][Full Text] [Related]
11. [Successful topical treatment of chronic cutaneous leishmaniasis with paromomycin sulfate (15%) and methylbenzethonium chloride (12%)].
Schallreuter KU; Lemke KR
Hautarzt; 1994 Nov; 45(11):783-6. PubMed ID: 7822205
[TBL] [Abstract][Full Text] [Related]
12. Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double-blind control study.
el-On J; Halevy S; Grunwald MH; Weinrauch L
J Am Acad Dermatol; 1992 Aug; 27(2 Pt 1):227-31. PubMed ID: 1430361
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Paromomycin-Chloroquine Combination Therapy in Experimental Cutaneous Leishmaniasis.
Wijnant GJ; Van Bocxlaer K; Yardley V; Murdan S; Croft SL
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607026
[TBL] [Abstract][Full Text] [Related]
14. Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala.
Arana BA; Mendoza CE; Rizzo NR; Kroeger A
Am J Trop Med Hyg; 2001 Nov; 65(5):466-70. PubMed ID: 11716099
[TBL] [Abstract][Full Text] [Related]
15. Topical treatment of recurrent cutaneous leishmaniasis with ointment containing paromomycin and methylbenzethonium chloride.
el-On J; Weinrauch L; Livshin R; Even-Paz Z; Jacobs GP
Br Med J (Clin Res Ed); 1985 Sep; 291(6497):704-5. PubMed ID: 3929905
[No Abstract] [Full Text] [Related]
16. Development of topical treatment for cutaneous leishmaniasis caused by Leishmania major in experimental animals.
El-On J; Jacobs GP; Witztum E; Greenblatt CL
Antimicrob Agents Chemother; 1984 Nov; 26(5):745-51. PubMed ID: 6517557
[TBL] [Abstract][Full Text] [Related]
17. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis.
Moosavi Z; Nakhli A; Rassaii S
Int J Dermatol; 2005 Dec; 44(12):1064-5. PubMed ID: 16409282
[No Abstract] [Full Text] [Related]
18. Immunotherapy with Imiquimod increases the efficacy of Glucantime therapy of Leishmania major infection.
Khalili G; Dobakhti F; Mahmoudzadeh-Niknam H; Khaze V; Partovi F
Iran J Immunol; 2011 Mar; 8(1):45-51. PubMed ID: 21427495
[TBL] [Abstract][Full Text] [Related]
19. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study.
Soto J; Fuya P; Herrera R; Berman J
Clin Infect Dis; 1998 Jan; 26(1):56-8. PubMed ID: 9455509
[TBL] [Abstract][Full Text] [Related]
20. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru.
Miranda-Verástegui C; Llanos-Cuentas A; Arévalo I; Ward BJ; Matlashewski G
Clin Infect Dis; 2005 May; 40(10):1395-403. PubMed ID: 15844060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
